Reversible sensorineural hearing loss following administration of muromonab-CD3 (OKT3) for cadaveric renal transplant immunosuppression

Annals of Otology, Rhinology and Laryngology

Volumn 109, Issue 1, 2000, Pages 45-47

  Hartnick, Christopher J ^a,b   Smith, Richard V ^a   Greenstein, Stuart ^a   Tellis, Vivian ^a   Ruben, Robert J ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Muromonab CD3; OKT3; Ototoxicity; Sensorineural hearing loss

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; OKT 3;

ARTICLE; AUDIOMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT REJECTION; OTOTOXICITY; PERCEPTION DEAFNESS; PRIORITY JOURNAL; TOXICITY TESTING; TREATMENT OUTCOME;

EID: 0033977965     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940010900108     Document Type: Article

References (10)

1. Jung TT, Rhee CK, Lee CS, Park YS, Choi DC. Ototoxicity of salicylate, non-steroidal anti-inflammatory drugs, and quinine. Otolaryngol Clin North Am 1993;26:791-810.
2. Wallach PM, Love SR, Fiorica JV, Hoffman MS, Flannery MT. Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity. J Fla Med Assoc 1992;79:821-2.
3. Hartnick CJ, Cohen AF, Smith RV. Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3). Ann Otol Rhinol Laryngol 1997;106: 640-2.
4. Jackler RK, Brackmann DE. Neurotology. St Louis, Mo: Mosby-Year Book, 1994:629-50.
5. Matz G. Aminoglycoside ototoxicity. Am J Otol 1986;17: 117-9.
6. Kung PC, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive T-cell surface antigens. Science 1979;206:347-9.
7. Todd P, Brogden RN. Muromonab CD3: a review of its pharmacology and therapeutic potential. Drugs 1989;37:871-99.
8. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of renal cadaveric transplants. N Engl J Med 1985;313: 337-42.
9. Lim DJ. Effects of noise and ototoxic drugs at the cellular level in the cochlea: a review. Am J Otol 1986;7:73-98.
10. Mathog RH, Thomas WG. Hudson WR. Ototoxicity of new and potent diuretics. Arch Otolaryngol 1970;92:7-15.